SPRUCE BIOSCIENCES, INC. (SPRB) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$44.43

From 52W high−63.93%

Volume12260.00

Market cap$131.64M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$44.43

From 52W high

−63.93%

Volume

12260.00

Market cap

$131.64M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

46.5

MomentumView details →

1D Return

+7.00%

YTD Return

−49.16%

SummaryUpdated Jun 1, 2026

Spruce Biosciences, Inc. (NASDAQ:SPRB) is a biopharmaceutical company founded in 2014 and headquartered in Daly City, California. The company went public in October 2020 and has undergone a significant strategic transformation. Originally focused on developing treatments for congenital adrenal hyperplasia (CAH), Spruce pivoted in 2024 to acquire and develop Tralesinidase Alfa, an enzyme replacement therapy for a rare pediatric neurodegenerative disease called MPS IIIB (Mucopolysaccharidosis IIIB or Sanfilippo syndrome type B).

Ask drillr about SPRUCE BIOSCIENCES, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−61.33%

ROA (TTM)

−49.93%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+53.24%

FCF YoY

+16.88%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+47.46%

EBITDA YoY

−1.15%

MomentumView details →

1D Return

+7.00%

YTD Return

−49.16%

1Y Return

−57.79%

RSI (14)

46.5

vs 50D SMA

−10.68%

vs 200D SMA

−20.17%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

9.23x

Quick Ratio

9.23x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$6.68

EPS Surprise

−15.37%

Beats (12Q)

8/12

Next Q EPS Est

−$5.34

Avg Surprise (4Q)

−32.08%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−51.35M

Op. CF (TTM)

−42.62M

Next earningsNov 9, 2026 →

Latest newsMore news →

Spruce Biosciences hired Adrian Quartel as chief medical officer.75d ago

Similar companies

Jyong Biotech Ltd. Ordinary SharesMENS Foghorn Therapeutics Inc.FHTX Coherus Oncology, Inc.CHRS Compass Therapeutics, Inc.CMPX Molecular Partners AGMOLN Codexis, Inc.CDXS Find similar companies →

Latest newsMore news →

Spruce Biosciences launched MPS3BStudy.com, an online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB), enabling them to learn about and register interest in a related study.70d ago Spruce Biosciences hired Adrian Quartel as chief medical officer.75d ago Cure Sanfilippo Foundation and the National MPS Society agreed to make a combined $5.5 million strategic investment in Spruce Biosciences.84d ago